Henry Lik Yuen Chan

Summary

Affiliation: The Chinese University of Hong Kong
Country: China

Publications

  1. ncbi Virological response to different combination regimes of peginterferon alpha-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B
    Henry Lik Yuen Chan
    Institute of Digestive Disease and Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China
    Antivir Ther 12:815-23. 2007
  2. ncbi Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B
    Vincent Wai Sun Wong
    Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR
    Antivir Ther 13:571-9. 2008
  3. ncbi Genetic polymorphisms of interleukin-1-beta in association with sustained response to anti-viral treatment in chronic hepatitis B in Chinese
    H L Y Chan
    Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong
    Aliment Pharmacol Ther 23:1703-11. 2006
  4. ncbi Randomized trial of interferon beta-1a with or without ribavirin in Asian patients with chronic hepatitis C
    Henry L Y Chan
    The Chinese University of Hong Kong, Shatin, Hong Kong
    Hepatology 46:315-23. 2007
  5. ncbi Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B
    Vincent Wai Sun Wong
    Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong
    J Hepatol 54:236-42. 2011
  6. ncbi Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis
    H L Y Chan
    Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China
    J Viral Hepat 19:732-43. 2012
  7. ncbi Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinoma
    Stephen L Chan
    State Key Laboratory in Oncology in South China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong
    Liver Int 32:271-8. 2012
  8. ncbi Phylogenetic, virological, and clinical characteristics of genotype C hepatitis B virus with TCC at codon 15 of the precore region
    Henry Lik Yuen Chan
    Department of Medicine and Therapeutics and Institute of Digestive Diseases, 9 F Prince of Wales Hospital, The Chinese University of Hong Kong, 30 32 Ngan Shing Street, Shatin, Hong Kong, Hong Kong
    J Clin Microbiol 44:681-7. 2006
  9. ncbi A review of the natural history of chronic hepatitis B in the era of transient elastography
    Henry Lik Yuen Chan
    Department of Medicine and Therapeutics and Institute of Digestive Disease, Chinese University of Hong Kong, New Territories, Hong Kong SAR, China
    Antivir Ther 14:489-99. 2009
  10. ncbi Hepatitis B virus genotype C is associated with more severe liver fibrosis than genotype B
    Henry Lik Yuen Chan
    Department of Medicine and Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China
    Clin Gastroenterol Hepatol 7:1361-6. 2009

Collaborators

Detail Information

Publications127 found, 100 shown here

  1. ncbi Virological response to different combination regimes of peginterferon alpha-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B
    Henry Lik Yuen Chan
    Institute of Digestive Disease and Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China
    Antivir Ther 12:815-23. 2007
    ..To investigate whether simultaneous commencement of peginterferon alpha-2b and lamivudine treatment has more potent hepatitis B virus (HBV) DNA suppression than staggered regimes...
  2. ncbi Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B
    Vincent Wai Sun Wong
    Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR
    Antivir Ther 13:571-9. 2008
    ..The long-term efficacy of lamivudine treatment for patients suffering from severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B is unknown...
  3. ncbi Genetic polymorphisms of interleukin-1-beta in association with sustained response to anti-viral treatment in chronic hepatitis B in Chinese
    H L Y Chan
    Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong
    Aliment Pharmacol Ther 23:1703-11. 2006
    ..Interleukin-1beta is a pro-inflammatory cytokine that may influence host defence against viral infection...
  4. ncbi Randomized trial of interferon beta-1a with or without ribavirin in Asian patients with chronic hepatitis C
    Henry L Y Chan
    The Chinese University of Hong Kong, Shatin, Hong Kong
    Hepatology 46:315-23. 2007
    ..The addition of ribavirin to IFN beta-1a significantly increased the proportion of patients who achieved an SVR versus IFN beta-1a monotherapy...
  5. ncbi Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B
    Vincent Wai Sun Wong
    Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong
    J Hepatol 54:236-42. 2011
    ..Lamivudine was used in most previous studies, but the drug was limited by the development of resistance. Our objective is to study the safety and efficacy of entecavir in patients with severe acute exacerbation...
  6. ncbi Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis
    H L Y Chan
    Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China
    J Viral Hepat 19:732-43. 2012
    ..Telbivudine compared to lamivudine was associated with a higher rate of patients with both viral suppression and ALT normalization, a trend towards a higher rate of survival and significant improvement in glomerular filtration...
  7. ncbi Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinoma
    Stephen L Chan
    State Key Laboratory in Oncology in South China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong
    Liver Int 32:271-8. 2012
    ..In patients who subsequently develop HCC, the impact of antiviral therapy on the outcome of HCC remains unclear...
  8. ncbi Phylogenetic, virological, and clinical characteristics of genotype C hepatitis B virus with TCC at codon 15 of the precore region
    Henry Lik Yuen Chan
    Department of Medicine and Therapeutics and Institute of Digestive Diseases, 9 F Prince of Wales Hospital, The Chinese University of Hong Kong, 30 32 Ngan Shing Street, Shatin, Hong Kong, Hong Kong
    J Clin Microbiol 44:681-7. 2006
    ..43). In summary, we report that HBV with TCC at nucleotides 1856 to 1858 of the precore region might represent a specific HBV strain associated with more aggressive liver disease than other genotype C HBV strains...
  9. ncbi A review of the natural history of chronic hepatitis B in the era of transient elastography
    Henry Lik Yuen Chan
    Department of Medicine and Therapeutics and Institute of Digestive Disease, Chinese University of Hong Kong, New Territories, Hong Kong SAR, China
    Antivir Ther 14:489-99. 2009
    ..In this review, new insights from studies using transient elastography on the natural history of chronic hepatitis B with special focus on liver fibrosis will be summarized and discussed...
  10. ncbi Hepatitis B virus genotype C is associated with more severe liver fibrosis than genotype B
    Henry Lik Yuen Chan
    Department of Medicine and Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China
    Clin Gastroenterol Hepatol 7:1361-6. 2009
    ..Histologic analyses of liver fibrosis have been limited by small sample sizes and the predominance of samples from patients with active hepatitis...
  11. ncbi Chronic hepatitis B in Asia-new insights from the past decade
    Henry Lik Yuen Chan
    Department of Medicine and Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong, China
    J Gastroenterol Hepatol 26:131-7. 2011
    ..Properly performed cost-effective analysis and understanding on the best timing of stopping antiviral drugs will be important to facilitate the most appropriate allocation of resources...
  12. ncbi Epidemiological and virological characteristics of 2 subgroups of hepatitis B virus genotype C
    Henry L Y Chan
    Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, People s Republic of China
    J Infect Dis 191:2022-32. 2005
    ..We aimed to investigate the characteristics of hepatitis B virus (HBV) genotype C subgroups in Hong Kong and their relationship with HBV genotype C in other parts of Asia...
  13. ncbi Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B
    Henry Lik Yuen Chan
    Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China
    Hepatology 41:1357-64. 2005
    ..In conclusion, combination treatment of peginterferon and lamivudine has a higher sustained virological response than lamivudine monotherapy up to 3 years after treatment...
  14. ncbi A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B
    Henry Lik Yuen Chan
    Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China
    Hepatology 52:1232-41. 2010
    ..CONCLUSION: HBsAg remained stable in HBeAg-positive patients and tended to reduce slowly in HBeAg-negative patients. Reduction of HBsAg for >1 log IU/mL could reflect improved immune control...
  15. ncbi Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B
    Henry Lik Yuen Chan
    Department of Medicine and Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong
    Antivir Ther 11:465-71. 2006
    ..In conclusion, extended lamivudine treatment is associated with a high maintained virological response and a low rate of drug resistance in severe acute exacerbation of HBeAg-negative chronic hepatitis B...
  16. ncbi Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B
    H L Y Chan
    Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China
    J Viral Hepat 16:36-44. 2009
    ..In conclusion, transient elastography is a reasonable noninvasive tool to substitute liver biopsy among the lowest and highest risk patients for the assessment of liver fibrosis...
  17. ncbi Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylated interferon alpha2a (40 kda; PEGASYS)
    Henry L Y Chan
    Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China
    Antivir Ther 13:555-62. 2008
    ..We aimed to investigate the efficacy of pegylated interferon alpha2a (PEG-IFN-alpha2a) in these difficult-to-treat patients...
  18. ncbi Genotype-specific genomic markers associated with primary hepatomas, based on complete genomic sequencing of hepatitis B virus
    Joseph J Y Sung
    Department of Medicine and Therapeutics, 9 F Prince of Wales Hospital, The Chinese University of Hong Kong, NT, Shatin, Hong Kong
    J Virol 82:3604-11. 2008
    ..Different HBV genotypes may have different virologic mechanisms of hepatocarcinogenesis...
  19. ncbi Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response
    Henry Lik Yuen Chan
    Department of Medicine and Therapeutics, and Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China
    Clin Gastroenterol Hepatol 5:1462-8. 2007
    ....
  20. ncbi Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial
    Henry L Y Chan
    The Chinese University of Hong Kong, Shatin, Hong Kong, China
    Ann Intern Med 147:745-54. 2007
    ..The efficacy of nucleoside and nucleotide analogues for hepatitis B has been linked to the magnitude and durability of hepatitis B virus (HBV) suppression...
  21. ncbi Association of cytokine gene polymorphisms and liver fibrosis in chronic hepatitis B
    Henry L Y Chan
    Institute of Digestive Disease and Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong
    J Gastroenterol Hepatol 23:783-9. 2008
    ..We aimed to investigate the association of cytokine gene polymorphism and liver fibrosis among Chinese patients with chronic hepatitis B...
  22. ncbi Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial
    Henry Lik Yuen Chan
    Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China
    Antivir Ther 12:345-53. 2007
    ..We conducted a multicentre, double-blind, placebo-controlled, randomized study to investigate the efficacy of 2-year lamivudine treatment in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B...
  23. ncbi How should we manage patients with non-alcoholic fatty liver disease in 2007?
    Henry L Y Chan
    Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China
    J Gastroenterol Hepatol 22:801-8. 2007
    ..Lifestyle changes are the first line and mainstay of management...
  24. ncbi Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B
    H L Y Chan
    Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China
    Aliment Pharmacol Ther 25:891-8. 2007
    ..To determine the factors affecting the virological response to adefovir dipivoxil (ADV) among patients with lamivudine resistant chronic hepatitis B...
  25. ncbi Evaluation of impact of serial hepatitis B virus DNA levels on development of hepatocellular carcinoma
    Henry Lik Yuen Chan
    Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong, Shatin, Hong Kong
    J Clin Microbiol 47:1830-6. 2009
    ..0 +/- 1.4 log copies/ml in HCC patients versus 2.5 +/- 0.9 log copies/ml in control patients; P = 0.38). A high trough HBV DNA level was associated with a higher risk of HCC. Whether antiviral treatment could prevent HCC was uncertain...
  26. ncbi Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B
    H L Y Chan
    Department of Medicine and Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong, Shatin, Hong Kong SAR
    Aliment Pharmacol Ther 32:1323-31. 2010
    ..On-treatment predictors of response to peginterferon can guide individualization of therapy in chronic hepatitis B virus infection...
  27. ncbi JGH Foundation emerging leadership lecture. Significance of hepatitis B virus genotypes and mutations in the development of hepatocellular carcinoma in Asia
    Henry Lik Yuen Chan
    Institute of Digestive Diseases and Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China
    J Gastroenterol Hepatol 26:8-12. 2011
    ..The understanding of the carcinogenic mechanisms of these HBV strains may shed light into future therapeutics in the prevention and treatment of HBV-related HCC...
  28. ncbi Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients
    Henry L Y Chan
    Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China
    Antivir Ther 16:1249-57. 2011
    ..Here, we aimed to investigate the role of HBV DNA and hepatitis B surface antigen (HBsAg) monitoring to predict off-treatment sustained response...
  29. ncbi Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients
    Henry Lik Yuen Chan
    Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong
    J Infect Dis 204:408-14. 2011
    ..We studied whether quantification of serum HBsAg and HBV DNA levels could predict spontaneous HBsAg clearance in patients with negative hepatitis B e antigen (HBeAg)...
  30. ncbi Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report
    Henry Lik Yuen Chan
    Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong
    J Hepatol 55:1121-31. 2011
    ..In clinical practice, serum HBsAg level should be used together with, but not as a substitute for, HBV DNA...
  31. ncbi Use of hepatitis B virus DNA quantitation to predict hepatitis B e antigen reversion in cases of chronic hepatitis B
    Henry Lik Yuen Chan
    Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong SAR, China
    J Clin Microbiol 41:4793-5. 2003
    ..HBV DNA levels at HBeAg seroconversion (group I) and at initial visits (group II) were significantly lower among patients who were persistently negative for HBeAg than among those who underwent HBeAg reversion...
  32. ncbi Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment
    Henry Lik Yuen Chan
    Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong
    World J Gastroenterol 9:2695-7. 2003
    ..To investigate the association of hepatitis B virus (HBV) genotype and HBeAg seroconversion after nucleotide analogue treatment...
  33. ncbi Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma
    H L Y Chan
    Department of Medicine and Therapeutics, 9 F Prince of Wales Hospital, 30 32 Ngan Shing St, Shatin, Hong Kong, China
    Gut 53:1494-8. 2004
    ..Our aim was to study the independent risk factors and effect of HBV genotypes on HCC development in a prospective longitudinal cohort of chronic hepatitis B patients...
  34. ncbi Absence of impact of donor hepatic steatosis and posttransplantation lamivudine resistance in a patient with chronic hepatitis B
    H L Y Chan
    Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong, China
    Transplant Proc 36:2309-10. 2004
    ..Lamivudine monoprophylaxis for hepatitis B virus-related liver diseases post liver transplantation can be used in areas where hepatitis B immunoglobulin is not affordable...
  35. ncbi Early hepatitis B virus DNA suppression can predict virologic response to peginterferon and lamivudine treatment
    Henry Lik Yuen Chan
    Department of Medicine and Therapeutics and Institute of Digestive Disease, Chinese University of Hong Kong, Hong Kong SAR, China
    Clin Gastroenterol Hepatol 6:1022-6. 2008
    ..We aimed to investigate the early on-treatment HBV DNA response to predict sustained virologic response for peginterferon and lamivudine combination therapy...
  36. ncbi Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation
    Henry Lik Yuen Chan
    Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong
    J Med Virol 68:182-7. 2002
    ..In conclusion, patients transplanted for fulminant hepatitis B and cirrhotic patients in whom HBV DNA could be rendered PCR negative before liver transplantation are unlikely to develop YMDD mutation on lamivudine monoprophylaxis...
  37. ncbi Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B
    Vincent Wai Sun Wong
    Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong
    Hepatology 51:1945-53. 2010
    ..The duration of concomitant lamivudine treatment had no impact on any long-term response. CONCLUSION: Peginterferon has high durability in HBeAg-positive chronic hepatitis B patients with end-of-treatment virologic response...
  38. ncbi Interaction of adipokines and hepatitis B virus on histological liver injury in the Chinese
    Vincent Wai Sun Wong
    Institute of Digestive Disease, The Chinese University of Hong Kong, China
    Am J Gastroenterol 105:132-8. 2010
    ..Our objective was to test whether dysregulation of adipokines contributes to liver injury. We also studied whether viral factors affected adipokines, insulin resistance, and hepatic steatosis...
  39. ncbi On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients
    Grace Lai Hung Wong
    Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China
    Antivir Ther 16:165-72. 2011
    ..The performance of liver stiffness measurement (LSM) to monitor the changes in the severity of liver fibrosis in chronic hepatitis B (CHB) patients on antiviral treatment is uncertain...
  40. ncbi Evaluation of alanine transaminase and hepatitis B virus DNA to predict liver cirrhosis in hepatitis B e antigen-negative chronic hepatitis B using transient elastography
    Grace Lai Hung Wong
    Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China
    Am J Gastroenterol 103:3071-81. 2008
    ....
  41. ncbi Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography
    Vincent Wai Sun Wong
    Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China
    Gut 61:409-15. 2012
    ..New non-invasive tests allow accurate and safe assessment in healthy individuals. The aim of this study was to examine the prevalence of NAFLD and advanced fibrosis in the general Hong Kong Chinese population...
  42. ncbi High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma
    Henry Lik Yuen Chan
    Department of Clinical Oncology, Sir YK Pao Center for Cancer, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong
    J Clin Oncol 26:177-82. 2008
    ..We aimed to investigate the impact of hepatitis B virus (HBV) DNA and HBV genotypes/subgenotypes on the risk of hepatocellular carcinoma (HCC)...
  43. ncbi Surrogate end points and long-term outcome in patients with chronic hepatitis B
    Vincent Wai Sun Wong
    Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong
    Clin Gastroenterol Hepatol 7:1113-20. 2009
    ..It is unclear whether surrogate end points reported in clinical trials correlate with long-term outcome of patients with chronic hepatitis B...
  44. ncbi Genetic polymorphisms of adiponectin and tumor necrosis factor-alpha and nonalcoholic fatty liver disease in Chinese people
    Vincent Wai Sun Wong
    Institute of Digestive Disease, The Chinese University of Hong Kong, Tseung Kwan O Hospital, Hong Kong
    J Gastroenterol Hepatol 23:914-21. 2008
    ..This study aimed to investigate the genetic polymorphisms of adiponectin and TNF-alpha in Chinese NAFLD patients and their association with disease severity...
  45. ncbi Hepatitis B virus genotype C takes a more aggressive disease course than hepatitis B virus genotype B in hepatitis B e antigen-positive patients
    Henry Lik Yuen Chan
    Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong SAR, People s Republic of China
    J Clin Microbiol 41:1277-9. 2003
    ..Disease activity was greater in patients infected by HBV genotype C than in those infected by HBV genotype B in the HBeAg-positive phase but not after HBeAg seroconversion...
  46. ncbi Survival and prognostic indicators in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation
    Alex Yui Hui
    Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong ROC
    J Clin Gastroenterol 34:569-72. 2002
    ..To determine the 2-year survival and prognostic indicators of hepatitis B virus-related cirrhosis after the onset of hepatic decompensation...
  47. ncbi Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy
    Yanni Yan Ni Lui
    Department of Medicine and Therapeutics, Chinese University of Hong Kong, New Terrritories, Hong Kong
    Antivir Ther 15:145-55. 2010
    ..The roadmap approach is recommended to guide chronic hepatitis B treatment. We evaluated the cost-effectiveness of various treatment strategies in the global market...
  48. ncbi Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients
    Grace Lai Hung Wong
    Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China
    Clin Gastroenterol Hepatol 7:227-33. 2009
    ..We analyzed the clinical factors associated with advanced liver fibrosis in hepatitis B e antigen (HBeAg)-positive chronic hepatitis B patients...
  49. ncbi Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease
    Vincent Wai Sun Wong
    Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China
    Am J Gastroenterol 107:1862-71. 2012
    ..The aim of this study was to evaluate the performance of the new XL probe in patients with nonalcoholic fatty liver disease (NAFLD)...
  50. ncbi Performance of the new MELD-Na score in predicting 3-month and 1-year mortality in Chinese patients with chronic hepatitis B
    Vincent Wai Sun Wong
    Institute of Digestive Disease and Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Republic of China
    Liver Transpl 13:1228-35. 2007
    ..72 and 0.75, respectively) (P = 0.004) in predicting mortality. In conclusion, the new MELD-Na score is a valid model to predict mortality in patients with complications of chronic hepatitis B...
  51. ncbi Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years
    Vincent Wai Sun Wong
    Department of Medicine and Therapeutics, 9 F, Prince of Wales Hospital, 30 32 Ngan Shing Street, Shatin, Hong Kong
    Gut 59:969-74. 2010
    ..Patients with non-alcoholic steatohepatitis (NASH) have increased mortality and liver-related complications. In contrast, simple steatosis is considered benign and non-progressive...
  52. ncbi Quantitative assessment of fibrosis in liver biopsies from patients with chronic hepatitis B
    Alex Yui Hui
    Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong
    Liver Int 24:611-8. 2004
    ..Image analysis or morphometry has the theoretical advantage of providing truly quantitative data...
  53. ncbi High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B
    Vincent Wai Sun Wong
    Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong
    Int J Cancer 124:2766-70. 2009
    ..This may assist clinicians in selecting high-risk patients for HCC surveillance program...
  54. ncbi Hepatitis B virus infection and fatty liver in the general population
    Vincent Wai Sun Wong
    Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China
    J Hepatol 56:533-40. 2012
    ..In animal studies, expression of hepatitis B virus (HBV) proteins causes hepatic steatosis. We aimed to study the prevalence of fatty liver in people with and without HBV infection in the general population...
  55. ncbi Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis
    Henry Lik Yuen Chan
    Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong SAR, China
    Clin Transplant 18:295-300. 2004
    ..We aimed to investigate the clinical outcome of patients who develop lamivudine resistant hepatitis B virus mutants (YMDD mutants) after liver transplantation...
  56. ncbi Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis
    Vincent Wai Sun Wong
    Institute of Digestive Disease and Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China
    Am J Gastroenterol 103:1682-8. 2008
    ..Nonalcoholic fatty liver disease (NAFLD) is increasing in prevalence worldwide. This study aimed to validate the NAFLD fibrosis score in the Chinese population...
  57. ncbi High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis
    Vincent Wai Sun Wong
    Department of Medicine and Therapeutics, Prince of Wales Hospital, Shatin, Hong Kong, China
    Gut 60:829-36. 2011
    ..The aim of this study was to examine the prevalence of colorectal neoplasm in NAFLD patients and the risk of colorectal neoplasm in relation to the severity of NAFLD histology. Design Cross-sectional study...
  58. ncbi Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers
    Jiayun Shen
    Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong
    J Hepatol 56:1363-70. 2012
    ..We aimed at testing the accuracy of cytokeratin-18 fragment (CK-18), adipocyte fatty acid binding protein (AFABP) and fibroblast growth factor 21 (FGF21) for the diagnosis of NAFLD and NASH...
  59. ncbi Antiviral drug resistance testing in patients with chronic hepatitis B
    Vincent Wai Sun Wong
    Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, 30 32 Ngan Shing Street, Shatin, Hong Kong
    Dig Dis Sci 57:221-31. 2012
    ..Antiviral drugs against hepatitis B virus are limited by the emergence of drug resistance...
  60. ncbi Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases
    Grace Lai Hung Wong
    Institute of Digestive Disease, Chinese University of Hong Kong, Hong Kong SAR, China
    Clin Gastroenterol Hepatol 6:1027-35. 2008
    ..We aimed to study the diagnostic performance of LSM for histologic bridging fibrosis and cirrhosis in various chronic liver diseases and to investigate the effects of liver fibrosis distribution on LSM...
  61. ncbi High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers
    Grace Lai Hung Wong
    Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China
    Gastroenterology 137:525-31. 2009
    ..The long-term prognosis of peptic ulcers associated with neither Helicobacter pylori nor nonsteroidal anti-inflammatory drugs (NSAIDs) is unknown...
  62. ncbi Effect of prostaglandin E2 and prostaglandin I2 on PDGF-induced proliferation of LI90, a human hepatic stellate cell line
    Alex Yui Hui
    Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong
    Prostaglandins Leukot Essent Fatty Acids 71:329-33. 2004
    ..In vivo studies using animal models are needed to elucidate the effect of COX-2 inhibition by non-steroidal anti-inflammatory drugs or COX-2 inhibitor in hepatic fibrosis...
  63. ncbi Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease
    Vincent Wai Sun Wong
    Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong
    Gut 60:1721-7. 2011
    ..The aim of this study was to determine the role of fatty liver in predicting coronary artery disease and clinical outcomes in patients undergoing coronary angiogram...
  64. ncbi The effect of caffeine and alcohol consumption on liver fibrosis - a study of 1045 Asian hepatitis B patients using transient elastography
    Arlinking Ong
    Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China
    Liver Int 31:1047-53. 2011
    ..Role of caffeine consumption in chronic hepatitis B virus (HBV)-infected patients and the interaction with alcohol consumption is unclear...
  65. ncbi Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial
    Francis Ka Leung Chan
    Institute of Digestive Disease, Chinese University of Hong Kong, Shatin, Hong Kong SAR, China
    Lancet 369:1621-6. 2007
    ....
  66. ncbi Severe acute exacerbation of chronic hepatitis B: a unique presentation of a common disease
    Vincent Wai Sun Wong
    Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China
    J Gastroenterol Hepatol 24:1179-86. 2009
    ..Liver transplantation, particularly living donor liver transplantation, should be considered for patients who develop hepatic failure secondary to severe acute exacerbation...
  67. ncbi Glucose-regulated protein 78 is an intracellular antiviral factor against hepatitis B virus
    Yan Ma
    Stanley Ho Center for Emerging Infectious Diseases, School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China
    Mol Cell Proteomics 8:2582-94. 2009
    ..Induction of hepatic GRP78 may provide a novel therapeutic approach in treating HBV infection...
  68. ncbi The G1613A mutation in the HBV genome affects HBeAg expression and viral replication through altered core promoter activity
    Man Shan Li
    School of Biomedical Sciences, The Chinese University of Hong Kong, Shatin, NT, Hong Kong SAR, China
    PLoS ONE 6:e21856. 2011
    ..We also provide a possible molecular mechanism of this hotspot mutation to the increased viral load of HBV carriers, which increases the risk to HCC...
  69. ncbi Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis
    Grace Lai Hung Wong
    Institute of Digestive Disease and Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China
    Liver Int 28:79-87. 2008
    ..The survival benefit of surveillance for hepatocellular carcinoma (HCC) is controversial. Aim: We aimed to examine the survival benefit of HCC surveillance in chronic viral hepatitis...
  70. ncbi Efficacy of cap-assisted colonoscopy in comparison with regular colonoscopy: a randomized controlled trial
    Yuk Tong Lee
    Faculty of Medicine, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China
    Am J Gastroenterol 104:41-6. 2009
    ..Colonoscopy cannot be completed in up to 10% of cases. We postulate that cap-assisted colonoscopy (CAC), by fitting a mucosectomy cap to the tip of a colonoscope, could improve the outcome...
  71. ncbi Lamivudine monoprophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: a seven-year follow-up study
    Jenny L Limquiaco
    Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China
    J Med Virol 81:224-9. 2009
    ..No genotypic resistance to adefovir was detected. Lamivudine followed by adefovir salvage is effective for prophylaxis of recurrence of HBV after liver transplantation up to 7 years...
  72. ncbi Lipoprotein lipase activator ameliorates the severity of dietary steatohepatitis
    Jun Yu
    Institute of Digestive Disease, Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong, China
    Biochem Biophys Res Commun 356:53-9. 2007
    ..These findings indicate that NO-1886 is a potential therapeutic agent for steatohepatitis...
  73. ncbi A review of telbivudine for the management of chronic hepatitis B virus infection
    Yanni Y N Lui
    The Chinese University of Hong Kong, Department of Medicine and Therapeutics and Institute of Digestive Disease, Hong Kong SAR, China
    Expert Opin Drug Metab Toxicol 4:1351-61. 2008
    ..Research interests have focused on the development of potent and safe antiviral agents with low resistance rates. Telbivudine is a nucleoside analogue that has been approved for treatment of chronic hepatitis B...
  74. ncbi Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease
    Vincent Wai Sun Wong
    Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China
    Hepatology 51:454-62. 2010
    ..Liver biopsy may be considered in NAFLD patients with liver stiffness of at least 7.9 kPa...
  75. ncbi Evaluation of model for end stage liver disease (MELD)-based systems as prognostic index for hepatocellular carcinoma
    Jenny L Limquiaco
    Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China
    J Gastroenterol Hepatol 24:63-9. 2009
    ..Aim: We aimed to evaluate the performance of Model for End Stage Liver Disease (MELD) based CLIP and JIS to predict the prognosis of hepatocellular carcinoma (HCC)...
  76. ncbi Expression of a cyclo-oxygenase-2 transgene in murine liver causes hepatitis
    Jun Yu
    Department of Medicine and Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong, Shatin, NT, Hong Kong
    Gut 56:991-9. 2007
    ..However, it is not known whether overexpression of COX-2 in the liver is sufficient to promote activation or secretion of inflammatory factors leading to hepatitis...
  77. ncbi Hepatocellular carcinoma in the Asia pacific region
    Man Fung Yuen
    Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China
    J Gastroenterol Hepatol 24:346-53. 2009
    ..However, transmission of HCV by injection drug use, and rising prevalence of obesity and diabetes, both independent risk factors for HCC, may partly offset this decline...
  78. ncbi High level virion production and surface antigen expression with 1.5 copies of hepatitis B viral genome
    Qingming Dong
    Stanley Ho Centre for Emerging Infectious Diseases, School of Public Health, The Chinese University of Hong Kong, Hong Kong, China
    J Virol Methods 159:135-40. 2009
    ..The HBV-1.5X system may be a useful platform that assists the establishment of stable cell lines and transgenic mice for the investigation of viral pathogenesis, particularly for the various strains of HBV...
  79. ncbi Predictors of treatment response in chronic hepatitis B
    Grace L H Wong
    Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong, Shatin, the Hong Kong SAR, China
    Drugs 69:2167-77. 2009
    ..In conclusion, predictors of response are useful to provide the most appropriate antiviral therapy to the most suitable patients, in order to achieve the best response and improve the clinical outcome of chronic hepatitis B patients...
  80. ncbi Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma
    K C Allen Chan
    State Key Laboratory in Oncology in South China, Sir Y K Pao Centre for Cancer, Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China
    Clin Chem 54:1528-36. 2008
    ..We evaluated the analysis of circulating hypermethylated RASSF1A for detecting HCC and assessing its prognosis...
  81. ncbi The anti-inflammatory effect of celecoxib does not prevent liver fibrosis in bile duct-ligated rats
    Jun Yu
    Department of Medicine, Institute of Digestive Disease, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China
    Liver Int 29:25-36. 2009
    ..However, data on the progression of liver fibrosis after treatment by celecoxib are not available. This study aims to elucidate the effects of celecoxib on cholestatic liver fibrosis in rats...
  82. ncbi Treatment of chronic hepatitis B: focus on telbivudine
    Yanni Y N Lui
    Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China
    Expert Rev Anti Infect Ther 7:259-68. 2009
    ..This article provides an overview of the pharmacokinetics, clinical efficacies, resistance profile and safety of telbivudine. A comparison of telbivudine with other oral antiviral agents is also highlighted...
  83. ncbi Effect of celecoxib on experimental liver fibrosis in rat
    Alex Yui Hui
    Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong
    Liver Int 26:125-36. 2006
    ....
  84. ncbi Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy
    Joseph J Y Sung
    Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China
    Gastroenterology 128:1890-7. 2005
    ..This study aimed to determine whether intrahepatic hepatitis B virus (HBV) covalently closed circular (ccc) DNA and total HBV DNA levels at the end of therapy would predict sustained response to therapy...
  85. ncbi Specific COX-2 inhibitor, NS-398, suppresses cellular proliferation and induces apoptosis in human hepatocellular carcinoma cells
    Alfred S L Cheng
    Department of Medicine and Therapeutics, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, P R China
    Int J Oncol 23:113-9. 2003
    ..In conclusion, specific COX-2 inhibitor suppresses cell proliferation and induces apoptosis in HCC cell lines that express COX-2. Our finding suggests that COX-2 inhibition may offer a new approach for HCC chemoprevention...
  86. ncbi Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro
    Jun Yu
    Institute of Digestive Disease and Department of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, Hong Kong, China
    Hepatology 51:2008-19. 2010
    ..PPARgamma suppresses tumor cell growth through reducing cell proliferation and inducing G(2)/M phase arrest, apoptosis, and up-regulating growth differentiation factor-15. Thus, PPARgamma acts as a tumor-suppressor gene in the liver...
  87. ncbi Treatment of chronic hepatitis B in Asia-Pacific countries: is the Asia-Pacific consensus statement being followed?
    Joseph J Y Sung
    Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong
    Antivir Ther 15:607-16. 2010
    ..We aimed to determine whether clinicians in the Asia-Pacific region are treating patients with chronic hepatitis B according to the Asia-Pacific consensus statement on the management of chronic hepatitis B...
  88. ncbi Moderate coffee consumption reduces the risk of hepatocellular carcinoma in hepatitis B chronic carriers: a case-control study
    Winnie Wing Man Leung
    School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, The People s Republic of China
    J Epidemiol Community Health 65:556-8. 2011
    ..This study examined whether coffee has a similar protective effect when consumed in moderate quantities in chronic hepatitis B virus (HBV) carriers, a group at high risk of developing liver cancer...
  89. ncbi Heme oxygenase-1 protects against steatohepatitis in both cultured hepatocytes and mice
    Jun Yu
    Institute of Digestive Disease and Department of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China
    Gastroenterology 138:694-704, 704.e1. 2010
    ..Heme oxygenase-1 (HO-1), an antioxidant defense enzyme, has been shown to protect against oxidant-induced tissue injury. We investigated the role of HO-1 in nutritional steatohepatitis in vitro and in vivo...
  90. ncbi Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial
    Francis K L Chan
    Departments of Medicine and Therapeutics, The Chinese University of Hong Kong, Special Administrative Region of China, Hong Kong
    Lancet 359:9-13. 2002
    ..We hypothesised that eradication of H pylori infection would reduce the risk of ulcers for patients starting long-term NSAID treatment...
  91. ncbi Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding
    Francis K L Chan
    Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, Hong Kong, China
    N Engl J Med 352:238-44. 2005
    ..guidelines also recommend clopidrogel for patients who have major gastrointestinal intolerance of aspirin. We compared clopidogrel with aspirin plus esomeprazole for the prevention of recurrent bleeding from ulcers in high-risk patients...
  92. ncbi Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection
    Wai K Leung
    Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong
    Gastroenterology 125:1011-7. 2003
    ..Herein, we describe the clinical, pathologic, and virologic features of the intestinal involvement of this new viral infection...
  93. ncbi Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angiogenesis in hepatitis B virus-associated hepatocellular carcinoma
    Alfred S L Cheng
    Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong
    Int J Oncol 24:853-60. 2004
    ..Moreover, COX-2 up-regulates VEGF expression in HCC cells, possibly via PGs production. Selective inhibition of COX-2 may block HCC associated angiogenesis and thus provides a rational approach for treatment of this malignancy...
  94. ncbi Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study
    Terence C W Poon
    Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, New Territories, Hong Kong Special Administrative Region, China
    Clin Chem 51:328-35. 2005
    ..This study was designed to identify serum proteomic signatures associated with liver fibrosis and to develop a proteome-based fingerprinting model for prediction of liver fibrosis...
  95. ncbi Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab
    Winnie Yeo
    Department of Clinical Oncology, Stanley Ho Centre for Emerging Infectious Diseases, School of Public Health, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China
    J Clin Oncol 27:605-11. 2009
    ....
  96. ncbi Elucidation of the role of COX-2 in liver fibrogenesis using transgenic mice
    Jun Yu
    Institute of Digestive Disease and Department of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, NT, Hong Kong, China
    Biochem Biophys Res Commun 372:571-7. 2008
    ..This is the first report on the effect of COX-2 in liver fibrosis based on genetic mouse models. The results suggest that COX-2 does not appear to mediate the development of liver fibrosis...
  97. ncbi A1762T/G1764A mutations of hepatitis B virus, associated with the increased risk of hepatocellular carcinoma, reduce basal core promoter activities
    Qingming Dong
    Stanley Ho Centre for Emerging Infectious Diseases and Li Ka Shing Institute of Health Sciences, School of Public Health, Prince of Wales Hospital, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, N T, Hong Kong, China
    Biochem Biophys Res Commun 374:773-6. 2008
    ..We also show that T1762A and G1764A double mutations synergize the reduction of the promoter activity. A mechanism of HBV evasion from host immunoresponse that may facilitate disease development is also discussed...
  98. ncbi An intensive surveillance program detected a high incidence of hepatocellular carcinoma among hepatitis B virus carriers with abnormal alpha-fetoprotein levels or abdominal ultrasonography results
    Tony S K Mok
    Department of Clinical Oncology, Prince of Wales Hospital, School of Public Health, Chinese University of Hong Kong, Hong Kong Special Administrative Region, China
    J Clin Oncol 23:8041-7. 2005
    ..To study the incidence and treatment outcomes of hepatocellular carcinoma (HCC) detected in an intensive surveillance program (ISP) of hepatitis B virus (HBV) carriers...
  99. ncbi Multiplex detection of 60 hepatitis B virus variants by maldi-tof mass spectrometry
    Ju Luan
    Stanley Ho Centre for Emerging Infectious Diseases and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR
    Clin Chem 55:1503-9. 2009
    ..Such variations may confer drug resistance or affect virus replication capacity, resulting in failure of antiviral therapy...
  100. ncbi Quantitative subtyping of hepatitis B virus reveals complex dynamics of YMDD motif mutants development during long-term lamivudine therapy
    Chunming Ding
    Stanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Hong Kong
    Antivir Ther 11:1041-9. 2006
    ..Treatment of chronic hepatitis B (CHB) with lamivudine (3TC) is limited by development of drug-resistant mutants at the YMDD motif. We aimed to validate the use of mass spectrometry to detect YMDD mutants and quantify viral subpopulations...
  101. ncbi RNA interference targeting HBx suppresses tumor growth and enhances cisplatin chemosensitivity in human hepatocellular carcinoma
    Alfred S L Cheng
    Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong
    Cancer Lett 253:43-52. 2007
    ..These results suggest that RNA interference-mediated HBx suppression exerts potent anti-proliferative and chemosensitizing effects in human HCC...